Sermorelin

Sermorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), a naturally occurring peptide hormone produced in the hypothalamus. It is comprised of the first 29 amino acids of the full 44-amino acid GHRH sequence. Sermorelin functions by binding to GHRH receptors in the pituitary gland, stimulating the release of endogenous growth hormone (GH). This mechanism differs from direct GH administration, as Sermorelin amplifies the body's own GH production rather than introducing exogenous GH.

The current research landscape surrounding Sermorelin is diverse, encompassing both its original intended use in pediatric growth hormone deficiency and more recent investigations into its potential applications in anti-aging, body composition, and even oncology. While initially developed and approved for diagnosing and treating growth hormone deficiency in children, its use has expanded, particularly in the context of age management clinics and wellness programs. A significant portion of the available clinical trial data stems from studies conducted decades ago, such as the large observational study sponsored by Eli Lilly and Company involving over 22,000 children receiving somatropin treatment, which, while not directly evaluating Sermorelin, provides context for growth hormone-related therapies. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) sponsored a terminated study involving over 3,000 participants, highlighting the broad interest in endocrine studies. More recent studies, such as the one conducted by the University of Roma La Sapienza involving 447 participants, have examined the relationship between growth hormone deficiency, empty sella, and cardio-metabolic risk factors in obesity.

Research papers indicate a growing interest in GHRH antagonists, including studies on MIA-602, a GHRH receptor antagonist. These studies explore the potential of GHRH antagonism in various conditions, including attenuating cardiopulmonary injury induced by SARS-CoV-2 in hACE2 mice, inhibiting inflammation induced by SARS-CoV-2 spike protein, and as a novel approach for the treatment of acute myeloid leukemia (AML). Furthermore, research suggests that GHRH antagonists may increase radiosensitivity in non-small cell lung cancer cells. Conversely, some research indicates a potential role of GHRH in tumorigenic transformation of human prostatic epithelial cells. These diverse findings underscore the complexity of the GHRH pathway and the need for further research to fully understand its implications in various physiological and pathological processes.

Sermorelin's safety profile, based on available data, appears relatively favorable. FDA adverse event data indicates a total of 55 reports, with none classified as serious. The most common reported reactions include pruritus, hypersensitivity, nausea, rash, and anaphylactic reaction. However, it is important to note that this data represents reported events and may not reflect the true incidence of adverse reactions.

From a regulatory standpoint, Sermorelin is FDA-approved, but its use is largely unregulated in many contexts. It is not categorized as a Category 2 substance, meaning it is not banned from compounding pharmacies. This allows for compounded formulations of Sermorelin to be readily available, contributing to its widespread use outside of its original FDA-approved indication.

The typical users of Sermorelin vary depending on the context. Initially, it was primarily used in pediatric endocrinology to diagnose and treat growth hormone deficiency. However, its use has expanded to include adults seeking anti-aging benefits, improved body composition, and enhanced sleep quality. These individuals often obtain Sermorelin through age management clinics or wellness programs, where it is prescribed off-label. The ongoing research into GHRH agonists and antagonists suggests a dynamic future for this class of peptides, with potential applications extending beyond its initial therapeutic scope, although the regulatory landscape surrounding its use in these contexts remains somewhat ambiguous.